Impact of STAS and LVI on Prognosis in Non-Small Cell Lung Cancer

Overview

This study analyzed 352 non-small cell lung cancer (NSCLC) patients to assess the prognostic significance of spread through air spaces (STAS) and lymphovascular invasion (LVI). STAS was found in 59.1% of cases and was significantly associated with poorer recurrence-free survival (RFS) and overall survival (OS), whereas LVI did not show a significant independent effect on survival outcomes.

Background

Lung carcinoma remains the leading cause of cancer mortality worldwide. Prognosis is primarily determined by TNM staging, but additional pathological features such as STAS and LVI may influence outcomes. STAS is characterized by tumor cells spreading within alveolar spaces adjacent to the tumor, and is linked to increased recurrence risk, especially in early-stage adenocarcinoma. LVI involves tumor invasion into lymphatic or blood vessels, facilitating nodal and distant metastasis and is considered a high-risk factor in NSCLC management guidelines.

Data Highlights

Key Findings

• STAS was detected in 208 of 352 NSCLC cases (59.1%), more frequently in adenocarcinoma.
• Univariable Cox regression identified age, lymph node invasion, stage, and STAS as significant predictors of recurrence-free and overall survival.
• Lymphovascular invasion did not independently predict survival outcomes in this cohort.
• Tumor size and pleural invasion were not significantly associated with survival, possibly due to stage distribution and other confounding factors.
• STAS is morphologically characterized by micropapillary clusters, solid nests, and single tumor cells within alveolar spaces beyond the tumor edge.
• Immunohistochemical staining helped differentiate STAS from alveolar macrophages, improving diagnostic accuracy.

Clinical Implications

Recognition of STAS as an independent adverse prognostic factor suggests its potential utility in risk stratification and treatment planning for NSCLC patients. Although LVI is traditionally considered high risk, its lack of independent prognostic significance here indicates that STAS may be a more critical pathological feature to consider. Incorporating STAS assessment into routine pathological evaluation could guide decisions regarding adjuvant therapy, especially in early-stage disease.

Conclusion

STAS is a prevalent and significant pathological feature in NSCLC that independently predicts poorer survival outcomes, underscoring its importance beyond conventional TNM staging. LVI, while clinically relevant, did not independently affect prognosis in this study, highlighting the need for further research to clarify its role.

References

1. WHO Classification of Lung Tumors -- 2015
2. Kadota et al. -- STAS Definition and Morphology
3. NCCN NSCLC Guidelines -- Vascular Invasion and Treatment